Summary
Initial clinical trials have demonstrated that uridine (Urd) rescue given i.v. over at least 3 days can ameliorate 5-fluorouracil (FUra) toxicity; to avoid Urd-induced phlebitis in the peripheral veins of patients, a central vein is used. The latter necessity, along with the need for 3 days of i.v. administration, makes Urd rescue by parenteral means a cumbersome and complicated clinical procedure. It would appear preferable to use oral Urd; however, the oral Urd dose in the clinic is limited, as high doses cause diarrhea. Therefore, using a tumor-bearing murine model we investigated as to whether low doses of oral Urd coupled with a Urd phosphorylase inhibitor benzylacyclouridine (BAU), would effect safe rescue of FUra toxicity with preservation of antitumor activity. A high-dose FUra-containing drug combination that included parenteral Urd rescue was used as a control; other groups of tumor-bearing mice received the same drug combination, except that p.o. Urd was substituted for i.p. Urd. In the absence of BAU, p.o. Urd could effect rescue while maintaining an antitumor effect comparable to that obtained with i.p. Urd. When given concomitantly with BAU, a 50% reduction in the oral Urd dose (i.e., from 4,000 to 2,000 mg/kg) enabled the achievement of a comparable therapeutic index. Intraperitoneal Urd produces very high (6–8 mM) plasma and tissue Urd levels, which remain above 100 μM for at least 6 h. In contrast, neither oral Urd nor oral BAU alone raised plasma Urd concentrations above about 50 μM. However, the combination of oral Urd plus oral BAU gave a peak plasma Urd level of about 300 μM, and the level was maintained above 100 μM for 6 h. Following oral Urd administration, gut tissue levels of Urd were in the mM range and those of BAU were in the range of 10–20 μg/g tissue, a level sufficient to result in substantial inhibition of Urd phosphorylase. Oral Urd plus oral BAU appears to be a promising clinical alternative to parenteral administration of Urd for selective rescue of FUra toxicity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- BAU:
-
benzylacyclouridine
- FUra:
-
5-fluorouracil
- (FUra)RNA:
-
RNA containing incorporated FUra
- LV:
-
leucovorin
- MTX:
-
methotrexate
- PALA:
-
N-phosphonacetyl-l-aspartate
- Urd:
-
uridine
References
Au J LS, Wientjes G, Bramer SL (1988) Effect of uridine coadministration on 5′-deoxy-5-fluorouridine disposition in rats. Cancer Chemother Pharmacol 22: 5–10
Chu MYW, Naguib FNM, Iltzsch MH, Kouni MH el, Chu SH, Cha S, Calabresi P (1984) Potentiation of 5-fluoro-2′-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine. Cancer Res 44: 1852–1856
Darnowski JW, Handschumacher RE (1985) Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res 45: 5364–5368
Darnowski JW, Handschumacher RE (1986) Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res 46: 3490–3494
Darnowski JW, Handschumacher RE (1988) Benzylacyclouridine-pharmacokinetics, metabolism and biochemical effects in mice. Biochem Pharmacol 37: 2613–2618
Handschumacher RE, Miller AM, Levy EJ (1983) Tissue selective effects of benzylacyclouridine on the utilization of circulating uridine. Proc Am Assoc Cancer Res 24: 300
Hartmann HR, Bollag W (1986) Modulation of the effects of fluoropyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine. Med Oncol Tumor Pharmacother 3: 111–118
Kemeny N, Bertino J, Doughtery J, Kelsen D, Schneider A, Sawyer R, Colofiore J, Martin D (1988) Phase I trial of PALA + methotrexate + 5-fluorouracil + leucovorin in the treatment of patients with metastatic cancer with the addition of uridine as a rescue agent for 5-fluorouracil. Memorial Sloan Kettering Cancer Center, New York
Klubes P, Cerna L (1983) Uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res 43: 3182–3186
Klubes P, Cerna I, Meldon MA (1982) Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol 8: 17–21
Klubes P, Geffen DB, Cysyk RL (1986) Comparison of the bioavailability of uridine in mice after either oral or parenteral administration. Cancer Chemother Pharmacol 17: 236–240
Levya A, Van Groeningen CJ, Kraal I, Gall H, Peters GJ, Landelma J, Pinedo HM (1984) Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res 44: 5928–5933
Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275
Martin DS (1987) Biochemical modulation — perspectives and objectives. In: Harrap KR, Connors TA (eds) New avenues in developmental cancer chemotherapy. Academic Press, New York, pp 113–162
Martin DS (1987) Purine and pyrimidine biochemistry, and some relevant clinical and preclinical cancer chemotherapy research. In: Powis G, Prough RA (eds) Metabolism and action of anticancer drugs. Taylor & Francis, London, pp 91–140
Martin DS, Fugmmann RA, Stolfi RL, Hayworth PE (1975) Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep 5: 89–109
Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW (1982) High-dose 5-fluorouracil with delayed uridine “rescue” in mice. Cancer Res 42:3964–3970
Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW (1983) Improved therapeutic index with sequential N-phosphonacetyl-l-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue. Cancer Res 43: 4653–4661
Martin DS, Stolfi RL, Colofiore JR (1988) Failure of high-dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance? J Natl Cancer Inst 80: 496–501
Peters GJ, Van Dijk J, Van Groeningen C, Laurensse EJ, Leyva A, Lankelma J, Pinedo HM (1986) Toxicity and antitumor effect of 5-fluorouracil and its recue by uridine. Adv Exp Med Biol 195B: 121–128
Pinedo HM (1986) Development of new anti-cancer drugs. Med Oncol Tumor Pharmacother 3: 63–69
Sarosy G, Leyland-Jones BK, Zaharevitz D, Collins J, Allegra C, Cysyk R, Strong J, Cowan K, Myers C, Van Echo D (1987) Phase I and biochemical pharmacology study of uridine and 5-fluorouracil. National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Sawyer RC, Stolfi RL, Spiegelman S, Martin DS (1984) Effect of uridine on the metabolism of 5-fluorouracil in the CD8F1 murine mammary carcinoma system. Pharm Res 2: 69–75
Stolfi RL, Martin DS, Fugmann RA (1971) Spontaneous murine mammary adenocarcinoma: model system for evaluation of combined methods of therapy. Cancer Chemother Rep 55: 239–251
Van Groeningen CJ, Leyva A, Kraal I, Peters GJ, Pinedo HM (1986) Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 70: 745–750
Van Groeningen CJ, Leyva A, Peters GJ, Laurensee E, Pinedo HM (1986) Reversal of 5-fluorouracil (5-FU) induced myelosuppression by high dose uridine (UR). Proc Am Assoc Cancer Res 26: 169
Van Groeningen CJ, Peters G, Nadal J, Leyva A, Gal H, Pinedo H (1987) Phase I clinical and pharmacokinetic study of orally administered uridine. Proc Am Assoc Cancer Res 28: 195
Author information
Authors and Affiliations
Additional information
Supported in part by Public Health Service grant CA 25842 from the national Cancer Institute, National Institutes of Health, Department of Health and Human Services, and in part by a grant from the Chemotherapy Foundation of New York
Rights and permissions
About this article
Cite this article
Martin, D.S., Stolfi, R.L. & Sawyer, R.C. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother. Pharmacol. 24, 9–14 (1989). https://doi.org/10.1007/BF00254098
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254098